Slate Stone Wealth, LLC Tg Therapeutics, Inc. Transaction History

Slate Stone Wealth, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 04, 2022	SELL	$7.81 - $20.45 $112,831 - $295,441	-14,447 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$15.2 - $35.51 $77,520 - $181,101	-5,100 Reduced 26.09%	14,447 $274,000
Q3 2021 Oct 28, 2021	BUY	$21.78 - $40.45 $2,178 - $4,045	100 Added 0.51%	19,547 $651,000
Q2 2021 Aug 02, 2021	SELL	$32.5 - $48.96 $26,000 - $39,168	-800 Reduced 3.95%	19,447 $754,000
Q1 2021 Apr 19, 2021	BUY	$41.61 - $54.3 $106,105 - $138,465	2,550 Added 14.41%	20,247 $976,000
Q4 2020 Jan 25, 2021	BUY	$25.27 - $54.9 $48,013 - $104,310	1,900 Added 12.03%	17,697 $921,000
Q3 2020 Oct 27, 2020	BUY	$18.49 - $27.24 $18,490 - $27,240	1,000 Added 6.76%	15,797 $423,000
Q2 2020 Jul 29, 2020	BUY	$8.9 - $21.84 $131,693 - $323,166	14,797 New	14,797 $288,000

336

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.23B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Slate Stone Wealth, LLC, based on Form 13F filings with the SEC.

Stay updated on Slate Stone Wealth, LLC with notifications on news.